These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25499943)

  • 1. Liver histology during Mipomersen therapy for severe hypercholesterolemia.
    Hashemi N; Odze RD; McGowan MP; Santos RD; Stroes ESG; Cohen DE
    J Clin Lipidol; 2014; 8(6):606-611. PubMed ID: 25499943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.
    McGowan MP; Tardif JC; Ceska R; Burgess LJ; Soran H; Gouni-Berthold I; Wagener G; Chasan-Taber S
    PLoS One; 2012; 7(11):e49006. PubMed ID: 23152839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.
    Visser ME; Akdim F; Tribble DL; Nederveen AJ; Kwoh TJ; Kastelein JJ; Trip MD; Stroes ES
    J Lipid Res; 2010 May; 51(5):1057-62. PubMed ID: 20008831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genetics of familial hypercholesterolemia and emerging therapies.
    Vogt A
    Appl Clin Genet; 2015; 8():27-36. PubMed ID: 25670911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Casimersen (AMONDYS 45™): An Antisense Oligonucleotide for Duchenne Muscular Dystrophy.
    Assefa M; Gepfert A; Zaheer M; Hum JM; Skinner BW
    Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unveiling Familial Hypercholesterolemia-Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy.
    Fularski P; Hajdys J; Majchrowicz G; Stabrawa M; Młynarska E; Rysz J; Franczyk B
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study.
    Zhuang W; Lu M; Wu Y; Chen Z; Wang M; Wang X; Guan S; Lin W
    Clin Drug Investig; 2023 Dec; 43(12):949-962. PubMed ID: 37995087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low LDL Cholesterol Is Not an Independent Risk Factor for Hepatic Steatosis.
    McHenry S; Awad A; Kozlitina J; Stitziel NO; Davidson NO
    Dig Dis Sci; 2023 Aug; 68(8):3451-3457. PubMed ID: 37291473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of dietary inflammatory index (DII) and central obesity with non-alcoholic fatty liver disease (NAFLD) in people with diabetes (T2DM).
    Soltanieh S; Salavatizadeh M; Poustchi H; Yari Z; Mansour A; Khamseh ME; Malek M; Alaei-Shahmiri F; Hekmatdoost A
    Heliyon; 2023 Mar; 9(3):e13983. PubMed ID: 36915483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA therapy for myocardial infarction: A review of targets and delivery vehicles.
    Wang X; Wu DH; Senyo SE
    Front Bioeng Biotechnol; 2022; 10():1037051. PubMed ID: 36507276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    Alhamadani F; Zhang K; Parikh R; Wu H; Rasmussen TP; Bahal R; Zhong XB; Manautou JE
    Drug Metab Dispos; 2022 Jun; 50(6):879-887. PubMed ID: 35221289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.
    Martínez-Arranz I; Bruzzone C; Noureddin M; Gil-Redondo R; Mincholé I; Bizkarguenaga M; Arretxe E; Iruarrizaga-Lejarreta M; Fernández-Ramos D; Lopitz-Otsoa F; Mayo R; Embade N; Newberry E; Mittendorf B; Izquierdo-Sánchez L; Smid V; Arnold J; Iruzubieta P; Pérez Castaño Y; Krawczyk M; Marigorta UM; Morrison MC; Kleemann R; Martín-Duce A; Hayardeny L; Vitek L; Bruha R; Aller de la Fuente R; Crespo J; Romero-Gomez M; Banales JM; Arrese M; Cusi K; Bugianesi E; Klein S; Lu SC; Anstee QM; Millet O; Davidson NO; Alonso C; Mato JM
    Hepatology; 2022 Oct; 76(4):1121-1134. PubMed ID: 35220605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia.
    Hu B; Li B; Li K; Liu Y; Li C; Zheng L; Zhang M; Yang T; Guo S; Dong X; Zhang T; Liu Q; Hussain A; Weng Y; Peng L; Zhao Y; Liang XJ; Huang Y
    Sci Adv; 2022 Feb; 8(7):eabm1418. PubMed ID: 35171673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Clinical Trials.
    Astaneh B; Makhdami N; Astaneh V; Guyatt G
    J Cardiovasc Dev Dis; 2021 Jul; 8(7):. PubMed ID: 34357325
    [No Abstract]   [Full Text] [Related]  

  • 15. Biotechnology Approaches for the Treatment of Dyslipidemia.
    Parolini C
    Cardiovasc Drugs Ther; 2021 Feb; 35(1):167-183. PubMed ID: 32519066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LDL-Cholesterol-Lowering Therapy.
    Pirillo A; Norata GD; Catapano AL
    Handb Exp Pharmacol; 2022; 270():73-101. PubMed ID: 32350699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis.
    Blom DJ; Raal FJ; Santos RD; Marais AD
    Curr Atheroscler Rep; 2019 Nov; 21(12):48. PubMed ID: 31741187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
    Darras BT; Farrar MA; Mercuri E; Finkel RS; Foster R; Hughes SG; Bhan I; Farwell W; Gheuens S
    CNS Drugs; 2019 Sep; 33(9):919-932. PubMed ID: 31420846
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.